Drug prices and trends for GNP NASAL DECONGEST ER

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP NASAL DECONGEST ER 120 MG	24385-0054-61	0.28661	EACH	2026-06-17
GNP NASAL DECONGEST ER 120 MG	24385-0054-61	0.28692	EACH	2026-05-20
GNP NASAL DECONGEST ER 120 MG	24385-0054-61	0.28527	EACH	2026-04-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: July 19, 2026

GNP NASAL DECONGEST ER (price, competition, and projected cost in the US market)

GNP NASAL DECONGEST ER is a private-label, over-the-counter (OTC) oral nasal decongestant product marketed under GNP. Because it is OTC (not subject to Hatch-Waxman exclusivity, Orange Book patent listings, or FDA NDA/BLA review milestones), the market is driven by: (1) ingredient-level competition, (2) pharmacy and warehouse club contracting, (3) distribution mix (mass, drugstore, club, ecommerce), and (4) periodic supplier cost swings. Price is primarily anchored to comparable OTC decongestant formats and store brand price ladders rather than prescription-style patent estates.

Price projection framework (high-level):

Base-case direction: flat-to-moderate inflation with promotional volatility.
Primary upside/downside drivers: wholesale ingredient costs, sustained demand for cold-and-allergy season, and retailer promotion depth.
No patent-based step-down: OTC generics are usually indistinguishable at the active-ingredient level, so “launch vs generic erosion” dynamics do not apply in the same way as prescription drugs.

What active ingredient is in GNP NASAL DECONGEST ER, and what does that mean for pricing?

Featured snippet: OTC pricing for GNP NASAL DECONGEST ER tracks the competitive basket of equivalent nasal decongestant active ingredients and dosage forms, not product-specific exclusivity.

For a defensible price model, the relevant variable is the exact active ingredient (and strength) plus form factor (extended-release nasal product) because retailers compare like-for-like. In OTC decongestants, the market’s pricing behavior is dominated by:

Therapeutic class substitutability: same active ingredient, same administration route, similar duration of effect.
Retail format substitutability: store brand versus national brand versus pharmacy private label.
Seasonality: demand spikes in fall and winter drive increased promo frequency rather than list price increases.

Pricing implication: Without ingredient and strength confirmation, projections should be treated as category-level. OTC category projections still can be made because pricing is set by distribution agreements and competition among equivalents, but item-level numeric targets require the specific formulation.

Which ingredient-led competitors set the price ladder for nasal decongestant ER OTC?

Retailers typically anchor ER nasal decongestant pricing against:

national brands with equivalent strength and ER dosing (where available in the same format)
pharmacy store brands
mass-market store brands
ecommerce bundled packs

How much of the US nasal decongestant ER market is controlled by private label vs national brands?

Featured snippet: Private label usually captures meaningful shelf share in OTC decongestants because consumers switch based on price with minimal perceived differentiation.

Market structure that affects GNP pricing:

Private label penetration increases when retailers run aggressive seasonal promotions.
National brand pricing power declines when store brands match the same active ingredient strength and route.
Channel mix drives weighted-average price:
- drugstores tend to run frequent promotions
- mass and club can sustain lower EDLP (everyday low price)
- ecommerce prices vary with marketplace competition and subscription/auto-replenishment

Business takeaway: GNP’s price is likely governed by retail contracting and promotional depth. Category conditions in cold-and-allergy season materially change the realized price.

When does GNP NASAL DECONGEST ER lose exclusivity or “generic protection,” and is there an Orange Book impact?

Featured snippet: There is no Orange Book exclusivity for OTC products; price declines follow competitive and promotional cycles rather than patent expiry.

Orange Book listings: prescription exclusivity mechanism. OTC decongestants are not generally covered by Hatch-Waxman exclusivity.
Patent-based step-down: if the product is OTC and formulation-level differentiation is limited, competitive erosion is driven by store brand equivalence rather than legal expiry.

Do Paragraph IV or biosimilar suits affect OTC decongestant pricing?

No. OTC decongestants are not biosimilars and do not face Paragraph IV frameworks tied to ANDA-to-Reference Listed Drug paths in the same way as prescription drugs.

What is the current price range for GNP NASAL DECONGEST ER in the US, and what are the retail promo patterns?

Featured snippet: Retail pricing for OTC decongestants is best modeled as an EDLP-plus-promotion system, where the seasonal promo discount determines realized revenue more than list price.

To produce precise price range numbers (e.g., “$X–$Y per unit”), this requires item-level pack size and strength, and live retail snapshots. Those data are not provided here.

However, a robust market model for projections uses:

Unit price (pack size normalized)
Promo frequency (events per season)
Promo depth (percent off vs EDLP)
Channel split (drugstore, mass, club, ecommerce)
Elasticity: price sensitivity typically high among OTC decongestant users

Projection implication: A category model can forecast annual movement, but precise dollar targets require the exact product configuration.

What price projections are realistic for the next 12–36 months for GNP NASAL DECONGEST ER?

Featured snippet: Base-case pricing is flat-to-up modestly with deeper promotions during peak cold-and-allergy months.

Category-driven base case (scenario planning, not item-specific pricing):

12 months: low single-digit nominal growth (driven by input and logistic costs), tempered by promotions
24–36 months: continued low single-digit nominal growth, with periodic dips during supplier cost relief or intensified private-label promotion

Key scenario switches

Downside scenario (lower realized prices):

retailer increases private label share
competitors intensify promotions
ingredient cost normalization reduces wholesale pressure

Upside scenario (higher realized prices):

ingredient cost increases
cold season severity drives reduced promo cadence
distribution constraints increase realized pricing via allocation and faster sell-through

Net expectation for business planning: realized unit margins may stay compressed even if list prices rise, because promotions are the principal demand tool.

How does retailer contracting, MAP policies, and ecommerce competition change projected prices?

Featured snippet: OTC decongestants show pricing dispersion across channels due to contractual terms and promo rules, not due to manufacturing exclusivity.

Channel mechanics that matter for forecasts

Retailer contracting: determines wholesale pass-through of ingredient cost changes.
Ecommerce marketplaces: can undercut in-market promo prices and compress realized margin.
Bundling: multi-pack deals lower average unit price and shift revenue recognition timing.

For projection modeling: use weighted-average price by channel, not a single “shelf” price.

What competitive threats exist from other OTC nasal decongestants, store brands, and switching substitutes?

Featured snippet: The biggest threat is substitution to equivalent active ingredient nasal decongestants and comparable ER formats sold at lower price points.

Common switching routes that compress GNP pricing

equivalent-strength store brands from other private label programs
national brand packs during promotional windows
alternative nasal decongestant delivery schedules (different ER durations) that still meet “longer relief” consumer intent

Business impact: in OTC decongestants, differentiation is thin, so competitive moves show up quickly in realized price and share.

What packaging and dosage-form differences affect price comparability for GNP NASAL DECONGEST ER?

Featured snippet: Unit price comparisons require normalization by strength, spray count, day-supply, and ER duration.

For price projections, comparable baskets must match:

active strength
ER dosing logic (duration claimed)
pack size (sprays or volume)
device format (spray pump, mist, etc.)

If those differ, category averages distort the forecast.

Does FDA regulation of OTC decongestants create pricing risk or forecast breaks?

Featured snippet: OTC decongestant pricing is less exposed to FDA approval cycles and more exposed to labeling/monograph compliance and supply stability.

Typical regulatory pricing impacts in OTC categories occur when:

labeling updates affect formulation or packaging runs
manufacturing compliance issues disrupt supply
enforcement actions force relabeling or product changes

These events are less frequent than market promo cycles but can cause short-term volatility.

What is the patent estate strength for GNP NASAL DECONGEST ER, and are there formulation patents that could change pricing?

Featured snippet: OTC decongestants are not generally priced on the basis of active, litigated exclusivity the way prescription drugs are.

This section cannot be completed with patent numbers, expiration dates, assignees, or jurisdictions because no patent or Orange Book/Drug Approval package identifiers were provided, and there is no reliable basis to generate a legal patent map for this specific product.

Key Takeaways

GNP NASAL DECONGEST ER is priced and forecast like an OTC commodity basket: retailer promotions and equivalent product substitution drive realized price.
There is no prescription-style exclusivity or Orange Book framework that produces a “patent expiry” driven price step-down.
Base-case expectation for 12–36 months is flat-to-modest nominal growth with promotional volatility during peak cold-and-allergy periods.
Item-level numeric price targets require normalization by active ingredient strength, ER duration, and pack size; without those, only directionality at category level can be modeled.

FAQs

1) How do I compare GNP NASAL DECONGEST ER pricing to national brands on an apples-to-apples basis?
Normalize by active strength and ER duration, then compare unit price per day of use.

2) What drives OTC nasal decongestant price changes most often?
Wholesale input costs, logistics, and retailer promotional depth during seasonal demand peaks.

3) Do OTC store brands undercut list prices permanently or only during promotions?
Often both: promotions set benchmarks that can lower realized prices even after the event.

4) Can supply disruptions raise GNP ER decongestant prices quickly?
Yes. Allocation and faster sell-through can temporarily lift realized pricing in constrained channels.

5) Is there any “generic entry risk” for GNP NASAL DECONGEST ER?
The risk is substitution by other equivalent OTC products, typically store brands, rather than ANDA/Paragraph IV-driven entry.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Drug Approval Reports and Drug Labeling Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases-drugs
FDA. (n.d.). OTC Drug Products. U.S. Food and Drug Administration. https://www.fda.gov/drugs/otc-drugs

Drug Price Trends for GNP NASAL DECONGEST ER

Average Pharmacy Cost for GNP NASAL DECONGEST ER